Mechanism of active shrinkage in mitochondria. I. Coupling between weak electrolyte fluxes.
1. A passive penetration of (NH4)2 HPO4 or of K2HPO4+nigericin occurs in respiratory-inhibited liver mitochondria. Addition of succinate at the end of the passive swelling initiates a shrinkage phase which leads to restoration of the initial mitochondrial volume. The rate and time of onset of the active shrinkage depend on the degree of stretching of the mitochondrial membrane. The rate of active shrinkage increases proportionally to the concentration of nigericin while it is strongly inhibited by valinomycin. 2. A number of SH inhibitors such as N-ethylmaleimide, p-chloromercuribenzoate, p-chloromercuriphenylsulphonate, dithiobisnitrobenzoate, exert a marked enhancing effect on the rate of shrinkage. The enhancing effect parallels titration of the phosphate carrier and inhibition of the passive phosphate efflux. In contrast, mersalyl is a powerful inhibitor of the rate of active shrinkage. The inhibition parallels that on phosphate passive efflux and requires higher mersalyl concentrations in respect to inhibition of phosphate influx. 3. The active shrinkage is discussed in terms of (a) a mechanoenzyme, (b) an electrogenic proton pump and (c) a proton-driven Pi pump.
D000818:Animals; D001693:Biological Transport, Active; D005033:Ethylmaleimide / Q000494:pharmacology; D066298:In Vitro Techniques; D008634:Mersalyl / Q000494:pharmacology; D008928:Mitochondria / Q000187:drug effects; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism*; D008933:Mitochondrial Swelling / Q000187:drug effects; D009550:Nigericin / Q000494:pharmacology; D010710:Phosphates / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D013439:Sulfhydryl Reagents / Q000494:pharmacology; D014634:Valinomycin / Q000494:pharmacology
D010710:Phosphates; D013439:Sulfhydryl Reagents; D014634:Valinomycin; D008634:Mersalyl; D005033:Ethylmaleimide; D009550:Nigericin